Waters Kevin

CFO Kevin Waters sells 25,000 PRCT shares for $1.8M at blended $72.47; holds 96.1K post-sale

Kevin Waters, EVP and CFO of PROCEPT BioRobotics, executed 3 separate sales totaling 25,000 shares for $1,811,653.29 on 2024-10-15, reducing his holdings by 20.6% from 121.1K to 96.1K shares. The blended average sale price of $72.47 significantly exceeds the current price of $69.08 (traded above current levels), occurring after the stock has declined 18.7% from its 52-week high of $84.99 and fallen 13.4% over the past 30 days. At the same ticker (PRCT), Waters' prior 5 trades show a pattern where neither of the 2 measurable 90-day sell outcomes were well-timed—both posted positive 90-day returns of +24.9% and +25.8%, meaning the stock rose after those sales. His three most recent sales at PRCT on 2024-09-16, all within 30 days prior, have already each declined 11.6% to 13.1% respectively, presenting a starkly different trajectory than his earlier 2024 trades at this ticker.

CFO Kevin Waters sold 25.0K shares for $2.1M at PRCT on 2024-09-16 near 52-week high

Kevin Waters, EVP and CFO of PROCEPT BioRobotics, executed 3 separate sales totaling 25,000 shares for $2,062,679.21 on 2024-09-16, reducing his holdings from 121,096 to 96,096 shares (a 20.6% reduction). The sales occurred at prices ($81.96, $82.69, $83.35) near the stock's 52-week high of $83.44, just 0.6% below the peak. While the stock has appreciated 26.5% over 30 days and 38.0% over 90 days, his prior 5 sales at PRCT have consistently underperformed on the 90-day horizon (none were well-timed by the 90-day measure), suggesting this timing pattern may not reflect prescient market positioning. The company remains unprofitable with net income of $-25,626,000.00 against quarterly revenue of $53,353,000.00, though annual revenue growth is strong at 81.6%.